Mary Wilson
Well-known member
August 31, 2021
JAMA Netw Open. 2021;4(8):e2122255.
doi:10.1001/jamanetworkopen.2021.22255
Ronen Shavit, MD[SUP]1[/SUP]; Ramit Maoz-Segal, MD[SUP]1[/SUP]; Mona Iancovici-Kidon, MD[SUP]1,2[/SUP]; Irena Offengenden, MD[SUP]1[/SUP]; Soad Haj Yahia, MD[SUP]1,2[/SUP]; Diti Machnes Maayan, MD[SUP]1,2[/SUP]; Yulia Lifshitz-Tunitsky, MD[SUP]1,2[/SUP]; Stanley Niznik, MD[SUP]1[/SUP]; Shirly Frizinsky, MD[SUP]1[/SUP]; Michal Deutch, BSN[SUP]1[/SUP]; Eti Elbaz, BSN[SUP]1[/SUP]; Hosney Genaim, BSN[SUP]1[/SUP]; Galia Rahav, MD, PhD[SUP]2,3[/SUP]; Itzchak Levy, MD[SUP]2,3[/SUP]; Anna Belkin, MD[SUP]2,3[/SUP]; Gili Regev-Yochay, MD[SUP]2,4[/SUP]; Arnon Afek, MD, MHA[SUP]2,5[/SUP]; Nancy Agmon-Levin, MD[SUP]1,2[/SUP]
Abstract
Importance Allergic reactions among some individuals who received the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine discourage patients with allergic conditions from receiving this vaccine and physicians from recommending the vaccine.
Objective To describe the assessment and immunization of highly allergic individuals with the BNT162b2 vaccine.
Design, Setting, and Participants In a prospective cohort study from December 27, 2020, to February 22, 2021, 8102 patients with allergies who applied to the COVID 19 vaccine referral center at the Sheba Medical Center underwent risk assessment using an algorithm that included a detailed questionnaire. High-risk patients (n = 429) were considered “highly allergic” and were immunized under medical supervision.
Exposures Pfizer-BioNTech (BNT162b2) COVID-19 vaccine.
Main Outcomes and Measures Allergic and anaphylactic reactions after the first and second doses of BNT162b2 vaccine among highly allergic patients.
Results Of the 429 individuals who applied to the COVID-19 referral center and were defined as highly allergic, 304 (70.9%) were women and the mean (SD) age was 52 (16) years ...
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783626
JAMA Netw Open. 2021;4(8):e2122255.
doi:10.1001/jamanetworkopen.2021.22255
Ronen Shavit, MD[SUP]1[/SUP]; Ramit Maoz-Segal, MD[SUP]1[/SUP]; Mona Iancovici-Kidon, MD[SUP]1,2[/SUP]; Irena Offengenden, MD[SUP]1[/SUP]; Soad Haj Yahia, MD[SUP]1,2[/SUP]; Diti Machnes Maayan, MD[SUP]1,2[/SUP]; Yulia Lifshitz-Tunitsky, MD[SUP]1,2[/SUP]; Stanley Niznik, MD[SUP]1[/SUP]; Shirly Frizinsky, MD[SUP]1[/SUP]; Michal Deutch, BSN[SUP]1[/SUP]; Eti Elbaz, BSN[SUP]1[/SUP]; Hosney Genaim, BSN[SUP]1[/SUP]; Galia Rahav, MD, PhD[SUP]2,3[/SUP]; Itzchak Levy, MD[SUP]2,3[/SUP]; Anna Belkin, MD[SUP]2,3[/SUP]; Gili Regev-Yochay, MD[SUP]2,4[/SUP]; Arnon Afek, MD, MHA[SUP]2,5[/SUP]; Nancy Agmon-Levin, MD[SUP]1,2[/SUP]
Abstract
Importance Allergic reactions among some individuals who received the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine discourage patients with allergic conditions from receiving this vaccine and physicians from recommending the vaccine.
Objective To describe the assessment and immunization of highly allergic individuals with the BNT162b2 vaccine.
Design, Setting, and Participants In a prospective cohort study from December 27, 2020, to February 22, 2021, 8102 patients with allergies who applied to the COVID 19 vaccine referral center at the Sheba Medical Center underwent risk assessment using an algorithm that included a detailed questionnaire. High-risk patients (n = 429) were considered “highly allergic” and were immunized under medical supervision.
Exposures Pfizer-BioNTech (BNT162b2) COVID-19 vaccine.
Main Outcomes and Measures Allergic and anaphylactic reactions after the first and second doses of BNT162b2 vaccine among highly allergic patients.
Results Of the 429 individuals who applied to the COVID-19 referral center and were defined as highly allergic, 304 (70.9%) were women and the mean (SD) age was 52 (16) years ...
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783626